Diagnostics Delivers, but Data Growth Still Needs to Earn Its Valuation

Results vs. Consensus

Q1 2026 Scorecard

Year-over-Year Comparisons

Quarter-over-Quarter Comparisons

Revenue assessment: Oncology unit growth of 28% supports durable demand. Hereditary’s reported 54% unit growth includes a full quarter of Ambry versus a February acquisition close last year; growth including pre-acquisition comparable volumes was 7%. The headline therefore overstates the underlying hereditary trajectory. New pharma wins improve forward visibility, but this quarter’s data growth was concentrated in existing relationships.

Margin assessment: Diagnostics generated $51.1M of the $66.8M increase in GAAP gross profit, about 76%. Data added $15.7M even as its margin fell. Non-GAAP operating expenses rose $55.1M against a $69.3M increase in adjusted gross profit, producing genuine incremental leverage. That is encouraging, but GAAP operating expenses rose $82.9M and the operating loss widened.

EPS assessment: The adjusted loss narrowed through operating improvement and lower net interest expense. The larger GAAP loss has a different explanation: the prior quarter a year ago included a $46.2M income-tax benefit, versus almost none now. Marketable-security losses were $32.3M versus $31.8M, so they explain the loss level much more than its deterioration. Stock compensation and related payroll taxes rose to $56.3M from $28.2M. Dilution and compensation remain economic costs even when removed from adjusted earnings.

Segment Performance

Diagnostics: Scale Is Becoming Visible in Gross Profit

Oncology tests increased to approximately 85,500 from 67,000. Higher throughput, a broader hereditary portfolio and revenue growing faster than diagnostic costs lifted gross margin by 500 basis points. Oncology revenue increased $34.0M; hereditary added $33.3M, with the latter heavily affected by the additional Ambry month. Diagnostics is already a material earnings engine rather than merely a channel for gathering data.

Assessment: We establish diagnostic scale as an on-track pillar. The key next step is sustaining laboratory economics as hereditary comparisons normalize and more tests enter the portfolio. Our FY2027 revenue forecast assumes diagnostics grows about 24%, with only a modest pricing contribution; it does not require the entire potential reimbursement uplift to arrive at once.

Data and Applications: Contracts Broaden, Recognized Growth Remains Concentrated

Insights licensing and modeling grew 44.1%, and bookings exceeded $100M for a third consecutive quarter. Merck’s new strategic collaboration and Gilead’s expansion show that the platform can attract and deepen relationships beyond its early partners. The economic attraction is repeated monetization of a clinical and molecular dataset across multiple research programs.

However, related-party revenue was $21.8M, or 25.1% of data revenue, versus $0.6M a year earlier. Its $21.2M increase represents 84.5% of the segment’s $25.1M growth. Revenue excluding the disclosed related-party amounts increased about 6.4%; that is a concentration diagnostic, not a company organic-growth measure. The Pathos foundation-model arrangement is a major contributor. Pathos can elect to pay up to half its data-license fees in preferred stock, reinforcing the distinction between a valuable collaboration and near-term cash proceeds.

Data costs increased 59%, including $5.9M of additional cloud costs, while revenue grew 40.5%. Non-GAAP data margin fell to 73.1% from 75.6%. AI model development creates a revenue opportunity and a compute bill; the current mix does not support assuming costless resale of every additional dollar.

Assessment: Data monetization is commercially on track, with an emerging concentration and cash-quality risk. New independent pharma agreements are the strongest counterweight to that risk. We expect 30% data growth in FY2027, but only a measured margin recovery, because a growing modeling component can remain more expensive to deliver than traditional data licensing.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management was confident about demand and dismissed the need for additional operating funding. Answers were more conditional on reimbursement timing and cash-flow cadence than on commercial momentum, which is the appropriate distinction for valuing the opportunity.

1. Pharma Model Building Deepens Relationships

Management described nearly half a dozen relationships involving agreements of $100M or more over multiple years. Customers typically progress from a narrow project into broader data access and model development. Dedicated teams, integration into drug development and repeated work across indications can increase switching costs beyond those of a one-off dataset purchase.

Assessment: Merck and Gilead strengthen the case for repeat demand, but their announced contract sizes do not translate directly into quarterly revenue. We expect the data business to outgrow diagnostics next year, with customer diversification more valuable to the multiple than another large headline booking from an existing related party.

2. Cash Conversion Has a Specific Q2 Test

Operating cash outflow was $73.3M despite an adjusted EBITDA loss of only $2.8M. The cash-flow statement includes $50.6M of accounts-payable outflow and $19.3M of deferred-revenue drawdown. Management attributed the seasonal pressure to payment timing and bonuses, and expects a significant Q2 improvement as some large Insights arrangements transition from prepaid balances to quarterly receipts.

The balance sheet supports that timing explanation, but it does not make recognized revenue equivalent to available cash. Free cash flow after $8.2M of equipment spending and $1.9M of capitalized software was negative $83.3M. The scale of Q1 outflow means later receipts must do more than track incremental EBITDA to recover the year’s cash position.

Assessment: The immediate issue is conversion, not an imminent liquidity shortage. We require Q2’s cash outflow to improve materially and the second-half EBITDA ramp to produce receipts. Failure on both would weaken the funding case even if reported sales remain near plan.

3. Reimbursement Can Lift Earnings, but Timing Matters

Management sees roughly $500 of possible oncology average-price uplift over the next year or two as assays secure regulatory and reimbursement progress. The xF submission carries no expected 2026 pricing benefit. An amendment covering tumor-only cases for the already approved assay could accelerate migration to the ADLT version, while RNA approval remains a further step.

Assessment: Higher reimbursement can carry attractive incremental margins because it raises revenue on tests already being performed. Our base forecast includes gradual benefit, not the full $500 uplift. A regulatory decision is an intermediate catalyst; the more valuable evidence is a sustained rise in realized collections per test.

4. Hereditary Recovery Depends on the Core Franchise

Management expects hereditary growth to return to the mid-teens in the second half as comparisons ease. RARE can improve revenue mix through higher-value testing, but its small volume cannot by itself move the much larger Ambry unit base. Management acknowledged that its whole-genome product reached the market later than a competitor’s, leaving the initial RARE contribution softer.

Assessment: We view the expected recovery as a combination of easier comparisons and better execution, rather than a new high-growth trajectory already established by Q1. Persistent single-digit comparable growth would challenge our diagnostic revenue forecast and reduce the room to fund newer assays from core earnings.

5. Workflow Adoption Is More Tangible Than Adjacent-Disease Optionality

Algorithms attached to about 40% of solid-tumor assays illustrate how RNA information and decision support can make the diagnostic offering more useful. Management’s strategy is to serve physicians from inherited risk through therapy selection and monitoring. A multiyear expansion into other diseases could extend the data market, but the current licensing business remains overwhelmingly oncology-based. An Alzheimer’s model project is an early commercial example, not evidence of a second scaled franchise.

Assessment: In our view, the near-term opportunity for AI is to strengthen physician retention and test demand. We give no separate valuation premium to neurology or an undemonstrated algorithm subscription stream. This keeps the investment case tied to clinical ordering and customer payments rather than the number of announced tools.

6. Investment Is Still Taking Most of the Incremental Gross Profit

The company retained its $65M adjusted EBITDA target while raising the revenue midpoint by 0.3%. That restraint is consistent with continued investment: adjusted operating expenses rose about 30% year-over-year. At the same time, $56.3M of quarterly stock compensation and payroll taxes exceeds most of the annual EBITDA target.

Assessment: Growth investment can be rational without generating an attractive per-share return at any price. Our forecast assumes adjusted expense growth slows below revenue growth in FY2027 and allows for further dilution. If expense growth continues around 30%, the anticipated margin expansion becomes difficult even with solid sales execution.

Guidance & Outlook

Implied remaining-year ramp: The $1.595B midpoint requires $1,246.9M of revenue over Q2–Q4, averaging $415.6M a quarter, about 19.4% above Q1. The EBITDA target requires $67.8M over the same period after Q1’s loss. Management expects the stronger second-half data contribution to improve mix and profitability as revenue scales.

Guidance assessment: The new midpoint is only $3M above the roughly $1.592B Street forecast. This is a small confirmation of demand, not a meaningful upward earnings reset. Q4 had generated $100.4M of data revenue versus $87.0M now, demonstrating why straight-line extrapolation from Q1 is inappropriate. The half-year weighting gives the plan a plausible path, while also concentrating execution risk later in the year. We do not assume a further beat solely because the opening quarter exceeded consensus.

Analyst Q&A Highlights

Cash Receipts Versus Adjusted Profit

Assessment: The answer identifies mechanisms that can be checked in Q2, but does not reconcile an annual free-cash-flow target. The funding reassurance is credible as a near-term liquidity statement; it is not evidence that EBITDA has already become distributable cash.

MRD Growth Is Being Deliberately Limited

“As reimbursement improves over time, you'll see us continue to roll that out more aggressively.”
— Eric Lefkofsky, Founder and CEO

Assessment: The constraint is unit economics rather than a demonstrated lack of demand. That distinction preserves long-term upside while limiting near-term revenue assumptions. The roughly 500% growth rate starts from a small base; faster unreimbursed volume would not automatically create shareholder value.

Can RARE Restore Hereditary Unit Growth?

Assessment: The answer usefully separates unit growth from price mix. We will judge the recovery through the large hereditary base, with RARE as an incremental revenue contributor. A mix benefit alone would not validate a return to the expected volume trajectory.

How Much of the Data Plan Is Already Visible?

Assessment: The pipeline-to-contract conversion supports our $415M FY2026 data forecast, modestly above that discussion framework. Remaining contract value includes customer options and opt-ins, and management did not allocate each new agreement to quarterly revenue or cash. The evidence raises confidence in the sales plan more than it narrows the cash-flow range.

Does the Growth Framework Already Include Better Reimbursement?

Assessment: The response does not establish that the whole price opportunity should be layered on top of 25% growth. Our FY2027 revenue estimate is about 25% above FY2026 and embeds modest pricing progress. Faster realized reimbursement would support the bull case; adding all potential uplift to the base would count optimism twice.

Do Companion Diagnostics Threaten Therapy-Selection Growth?

Assessment: The U.S. ordering explanation is plausible and consistent with current 28% oncology growth. It does not establish immunity from competitors. Continued unit growth and improved collections are stronger evidence of differentiation than a categorical dismissal of companion approvals.

What They're NOT Saying

1. A numerical annual cash-conversion bridge: Q2 improvement is the commitment, but the call does not quantify the full-year conversion of $65M EBITDA into cash after working capital, capital spending and interest. This keeps the valuation sensitive to financing needs.
2. The cash and margin contribution of each large data agreement: Commercial scope is clearer than customer-level collections, compute costs and profitability. Related-party participation and potential equity payment make those distinctions economically material.
3. A timetable for a fully reimbursed MRD rollout: The company explains why it is holding back, but does not supply an exact coverage threshold or date for broad sales deployment. We do not assign a discrete step-up quarter.
4. Measured algorithm economics: Attach rate is useful adoption evidence, yet incremental reimbursement, retention and profit from the algorithms are not separately quantified. Standalone software economics remain outside our base valuation.

Market Reaction

• Pre-print setup: TEM closed May 5 at $54.07, down 8.4% year to date and up 14.1% over the trailing 30-day trading lookback. Its trailing 12-month return was 0.0%, with a pre-print 52-week closing range of $42.37–$103.25.
• May 6 reaction session: Shares opened at $50.82, a 6.0% gap down, traded between $48.50 and $53.72, and closed at $53.50, down 1.1%. Volume was 10.7M shares, 2.1 times the preceding 30-day average.
• Market comparison: The S&P 500 rose 1.5% that session, while entering the print up 6.0% year to date. TEM’s session underperformance was therefore about 2.6 percentage points.

A limited raise met an already recovering share price. The 14.1% pre-print advance left less room for a small revenue beat and essentially unchanged earnings guidance to drive another rerating. The recovery from the opening gap shows the market did not sustain the initial degree of disappointment; the negative close against a rising index still signals an unmet expectation.

In our view, the tension is between attractive commercial growth and a distant per-share payoff. Contemporary reaction focused on the modest guide and wider loss, while the call supplied a constructive view of pharma demand. The filing’s concentration and cash data sharpen our own explanation of valuation risk; we cannot establish that they individually caused the session move.

Street Perspective

Debate: A Reusable Data Asset or a Concentrated Collaboration Business?

Bull view: Larger pharma relationships and repeated bookings demonstrate a scarce dataset becoming embedded in drug development.

Bear view: A few large arrangements can make the revenue base look broader and more recurring than its cash receipts, particularly where counterparties are related and payment may include equity.

Our take: Both models are present. Merck and Gilead strengthen the external validation, while related-party growth and declining data margins justify a discount to a mature subscription platform. Diversification and cash collections can earn a higher multiple; bookings alone cannot.

Debate: An AI Earnings Inflection or Continued Heavy Investment?

Bull view: Diagnostic scale supplies gross profit to fund AI tools, which improve ordering and create a second monetization stream.

Bear view: Compute, product development and stock compensation consume much of the upside before it reaches common shareholders.

Our take: Q1 supports improving adjusted operating leverage, with diagnostics doing most of the work. Our FY2027 EBITDA margin rises to 9%, requiring adjusted expenses to grow more slowly than sales. That is an achievable operating case, but still a demanding valuation starting point.

Debate: Reimbursement Optionality or a Reason to Wait?

Bull view: Better realized prices and a broader MRD launch could create upside with limited incremental selling infrastructure.

Bear view: Approval timing, payer coverage and partner losses can delay that opportunity while dilution continues.

Our take: The existing diagnostic franchise supports a viable base case without full reimbursement success. The optionality is real, but at $53.50 investors already pay for substantial growth. The best catalyst would be paid, profitable volume rather than a faster count of unreimbursed tests.

Our Estimates & Valuation Framework

We establish the following estimates from the Q1 result and current guidance. The FY2026 revenue estimate is at the new midpoint; FY2027 assumes continued oncology adoption, a return to mid-teens hereditary growth, gradual pricing improvement and a larger data business.

Estimate bridge: On unrounded FY2026 assumptions, $1.595B at 65.5% margin generates $1,044.7M of adjusted gross profit; $1,014.7M of adjusted operating costs leaves $30M of operating income. Adding $35M of retained depreciation and amortization yields $65M EBITDA. Q2–Q4 require an aggregate adjusted gross margin of about 65.6%, only modestly above Q1’s 65.0%. FY2027’s $405M revenue increase generates about $295M more gross profit; approximately $190M of expense growth and $10M more retained D&A account for the $115M EBITDA improvement. These are adjusted earnings, not GAAP profit or free cash flow.

Valuation method: We value FY2027 revenue over a 12-month horizon ending May 2027. At $53.50 and roughly 179.4M period-end common shares, equity value is about $9.60B. Adding about $594M of balance-sheet net debt and convertible obligations produces approximately $10.19B of enterprise value, or 6.4 times our FY2026 revenue and 5.1 times FY2027 revenue. Net debt here subtracts unrestricted cash and marketable securities, excludes restricted cash and includes the convertible promissory note; the securities are not risk-free cash.

The base calculation is ($2.00B × 6.0 − $0.65B) ÷ 190M = $59.74. The share allowance is roughly 6% above the period-end count to accommodate equity compensation and dilution. Convertible obligations remain debt in these scenarios, so conversion shares are not also added. The base net-debt allowance adds roughly $56M to the current $594M, leaving room for further cash consumption; the bear assumes weaker collections and the bull assumes better cash recovery.

Multiple discipline: Six times revenue is a demanding assumption that capitalizes continued growth and future margin improvement. At a hypothetical mature 20% EBITDA margin, it equates to 30 times EBITDA; it is not justified by the 4.1% margin guided for this year or our 9% forecast for next year. The bull multiple requires independent pharma adoption, pricing progress and better conversion. The bear’s 4.0 times sales reflects delayed reimbursement and lower confidence that data growth becomes recurring cash earnings. These are our valuation assumptions, not observed peer averages.

Every one-turn change in the base revenue multiple changes value by about $10.53 per share. A $100M revenue shortfall at that multiple costs about $3.16 per share before any accompanying multiple compression. The downside case therefore combines a sales miss with a lower price for each sales dollar, a credible risk for a business whose terminal margin remains far above today’s.

Return judgment: Assigning 60% to the base case, 25% to the bear and 15% to the bull produces a scenario-weighted value of $56.70, or approximately 6% upside. We assume no dividend. Against an illustrative 8% S&P 500 total return over the same 12 months, that is insufficient expected excess return for Outperform and close enough to market-like returns for Hold. The strong operating trajectory also prevents us from treating the downside case as the most likely outcome.

Thesis Scorecard Post-Earnings

We establish the following pillars in this first historical coverage note. There is no earlier house thesis available to grade; the operating benchmark is the company’s previously announced $1.59B revenue and $65M EBITDA plan.

What would change the view: Q2’s promised cash-flow improvement, second-half hereditary growth returning to the mid-teens, sustained external pharma wins and realized reimbursement gains would strengthen the case. We would reconsider the operating-leverage pillar if the $65M EBITDA objective falls or expense growth prevents the second-half ramp. A valuation near our bear-to-base midpoint without a comparable deterioration in the business would improve prospective returns; a higher multiple without improved cash economics would worsen them.

Overall: Diagnostic economics and adjusted leverage establish a constructive business thesis. Data concentration and the gap between adjusted profit and cash keep that thesis from warranting a premium stock rating.

Action: Hold. At $53.50, we see plausible growth but limited expected excess return after dilution, cash risk and downside are included. Management’s next task is to turn greater commercial visibility into a more reliable per-share cash outcome.